FDA gives go-ahead for MN166 (ibudilast) to begin phase 2b/3 clinical trials
After showing positive results in slowing the advancement of amyotrophic lateral sclerosis (ALS) in a previous study, ibudilast - brand name MN166 - has been given the green light by the FDA to start phase 2b/3 trials. This brings the medicine one step closer to approval for treatment of ALS.
MN166 (ibudilast) is a small molecule whose action decreases immune cell activity in the brain and boosts the survival and growth of nerve cells controlling movement. This new trial will assess ibudilast's capacity to delay ALS progression and functional disability in patients when compared with a placebo. The change in the patients’ muscle strength, quality of life, and ability to breathe will also be evaluated along with the medicine's safety and tolerability profile.
Additional information can be found on ALSNewsyToday.